UC7AI180308

Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University - Project Summary:

The Rocky Mountain Regional Biocontainment Laboratory (RMRBL) at Colorado State University (CSU) has been responsive to the national RBL mission to: 1) "conduct research on biodefense and emerging infectious disease agents"; 2) "be available and prepared to assist national, state, and local public health efforts in the event of a bioterrorism or infectious disease emergency" since its opening and full commissioning in 2008.

Researchers at the RMRBL and their collaborators rapidly pivoted in response to the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), working on host-derived therapeutics, vaccines, and identifying other potential zoonotic reservoirs as spillover opportunities in wildlife and domestic animals.

Our researchers similarly pivoted this past year to work on countermeasures in response to the re-emergence of MPOX, while also continuing to address high consequence pathogens that have chronically plagued public health systems, such as Mycobacterium tuberculosis, the causative agent of tuberculosis.

Beyond our demonstrated ability to rapidly address research and research service needs on pathogens with pandemic potential, our team contributes to training, outreach, and access of our facility via sponsored fellowships, visiting scholars' programs, workshops, conferences, and through collaborations.

Despite these gains, our RMRBL BSL3 suites are aged, requiring constant investments to maintain safe, secure and compliant BSL3 facilities. RMRBL BSL3 researchers, support staff, and biosafety professionals are vulnerable to the strain of the work environment, limited resources, funding gaps, and opportunities to engage in less risky fields equipped with cutting-edge technologies.

In this application, we respond to the challenges facing the RMRBL BSL3 laboratories with 3 cores. Core 1 includes an improved management structure, systematic replacement of deprecating scientific instruments, and comprehensive and proactive maintenance of existing facilities needs to ensure compliance and continuous functioning. Operation of the RMRBL BSL3 is additionally enhanced to improve the working environment and increase consistency for operations research support and animal husbandry staff.

Core 2's initiatives seek to develop training programs responsive to adult learning and education best practices, ensuring improved safety and safety compliance in persons working in the BSL3. Biosecurity upgrades will improve the safety and security climate in anticipation of new national standards, and integration between research teams and the Office of Biosafety in constructing and training in technical standard operating procedures will accelerate safe performance and technical competence.

Finally, Core 3 synthesizes our research strengths to develop a uniquely qualified biocontainment research resources core, bringing together opportunities to exploit team talent and perform innovative research. Combined, our three cores ensure that the RMRBL BSL3 facilities are always 'warm ready' – to face and combat the next pathogenic pandemic threat.

Colorado State University

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Colorado United States

State-Wide

Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed) (RFA-AI-22-075)

Amendment Since initial award the total obligations have increased 205% from $2,751,527 to $8,392,076.